Darinaparsin: a novel organic arsenical with promising anticancer activity

Bibliography

• Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6(Suppl 2):3-10
   PubMed Web of Science ®Google Scholar
• Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001;6(Suppl 2):1-2
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metabolism of inorganic arsenic and non-cancerous health hazards associated with chronic exposure in humans. J Environ Biol 2007;28(2 Suppl):349-57
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113(9):1875-91
   PubMed Web of Science ®Google Scholar
• Tallman MS. The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 2008;45(3 Suppl 2):S25-9
   PubMed Web of Science ®Google Scholar
• Hermine O, Dombret H, Poupon J, Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5(2):130-4
   PubMedGoogle Scholar
• Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10(5):370-4
   PubMedGoogle Scholar
• List A, Beran M, DiPersio J, Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17(8):1499-507
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94(10):3315-24
   PubMed Web of Science ®Google Scholar
• Konig A, Wrazel L, Warrell RP Jr, Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997;90(2):562-70
   PubMed Web of Science ®Google Scholar
• Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999;44(5):417-21
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A, Kobayashi M, Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway. Leuk Lymphoma 2004;45(5):987-95
   PubMed Web of Science ®Google Scholar
• Don AS, Kisker O, Dilda P, A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003;3(5):497-509
   PubMed Web of Science ®Google Scholar
• Golemovic M, Quintas-Cardama A, Manshouri T, MER1, a novel organic arsenic derivative, has potent PML-RARalpha- independent cytotoxic activity against leukemia cells. Invest New Drugs 2009; published online 26 May: doi:10.1007/s10637-009-9267-z
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Verstovsek S, Freireich E, Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem 2008;8(8):904-9
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol 2007;47:243-62
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhou L, Styblo M, Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003;63(8):1853-9
   PubMed Web of Science ®Google Scholar
• Ferrario D, Croera C, Brustio R, Toxicity of inorganic arsenic and its metabolites on haematopoietic progenitors “in vitro”: comparison between species and sexes. Toxicology 2008;249(2-3):102-8
   PubMed Web of Science ®Google Scholar
• Dopp E, Hartmann LM, Florea AM, Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol Appl Pharmacol 2004;201(2):156-65
   PubMed Web of Science ®Google Scholar
• Piatek K, Schwerdtle T, Hartwig A, Bal W. Monomethylarsonous acid destroys a tetrathiolate zinc finger much more efficiently than inorganic arsenite: mechanistic considerations and consequences for DNA repair inhibition. Chem Res Toxicol 2008;21(3):600-6
   PubMed Web of Science ®Google Scholar
• Matulis SM, Morales AA, Yehiayan L, Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther 2009;8(5):1197-206
   PubMed Web of Science ®Google Scholar
• Boise LH, Morales AA, Croutch C, S-dimethylarsinoglutatione (ZIO-101): a novel organic arsenic with a unique gene expression profile in myeloma [abstract]. American Association for Cancer Research Annual Meeting: Proceedings 2007;48 :abstract nr 4827
   Google Scholar
• Diaz Z, Mann KK, Marcoux S, A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008;22(10):1853-63
   PubMed Web of Science ®Google Scholar
• Wang ZG, Rivi R, Delva L, Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998;92(5):1497-504
   PubMed Web of Science ®Google Scholar
• Chou WC, Jie C, Kenedy AA, Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 2004;101(13):4578-83
   PubMed Web of Science ®Google Scholar
• Woo SH, Park IC, Park MJ, Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002;21(1):57-63
   PubMed Web of Science ®Google Scholar
• Manshouri T, Subbarao VK, Ashoori F, Comparison of uptake and iIntracellular induced structural changes of arsenic trioxide, an inorganic compound, and organic arsenic derivative S-dimethylarsinoglutathione (SGLU; ZIO-101) in NB4 Acute Promyelocytic leukemia (APL) cells [abstract]. Blood 2005;106 : abstract nr 4446
   Web of Science ®Google Scholar
• Manshouri T, Freireich E, Zingaro R, Organic and inorganic arsenics operate by different biochemical pathways to induce apoptosis in cancer cells. Eur J Cancer Suppl 2005;4(12):133
   Google Scholar
• Cheng X, Taghi M, Huang P, Mechanisms of increased reactive oxygen species (ROS) generation induced by organic arsenic derivative S-dimethylarsinoglutathione (SGLU; ZIO-101) [abstract]. Blood 2005;106 :abstract nr 4445
   Web of Science ®Google Scholar
• Heyfets A, Flescher E. A new organic arsenic derivate, darinaparsin, acts directly on isolated human cancer cell mitochondria. manuscript submitted
   Google Scholar
• Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341(Pt 2):233-49
   PubMedGoogle Scholar
• Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93(1):268-77
   PubMed Web of Science ®Google Scholar
• Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17(5):931-40
   PubMed Web of Science ®Google Scholar
• Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81(5):796-9
   PubMed Web of Science ®Google Scholar
• Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumors and normal tissue. Cancer 1993;72(3):783-7
   PubMed Web of Science ®Google Scholar
• Gutman D, Morales AA, Croutch CR, S-dimethylarsinoglutathione (ZIO-101) a novel arsenical with activtity in myeloma. Haematologica 2007;97(Suppl 2) :abstract nr PO-504
   Google Scholar
• Komarnitsky PB, Qu Z, Schwartz B, Wallner B. ZIO-101 an oral multi-targeted anti-cancer drug with anti-angiogenic activity [abstract]. American Association for Cancer Research Annual Meeting: Proceedings 2007;48 :abstract nr 4000
   Google Scholar
• Goldin A. Combined Chemotherapy. Oncology 1980;37(S1):3-8
   PubMedGoogle Scholar
• Campbell RA, Sanchez E, Chen H, ZIO-101, a novel organic arsenic, inhibits human myeloma cell growth in a SCID-hu model [abstract]. Blood 2006;108 :abstract nr 3462
   Web of Science ®Google Scholar
• Kala SV, Neely MW, Kala G, The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 2000;275(43):33404-8
   PubMed Web of Science ®Google Scholar
• Camacho LH, Kornblau S, Berenson JR, A new organic arsenic in advanced cancers. 18th EORTC-NCI-AACR Symposium of Molecular Targets and Cancer Therapeutics. Eur J Cancer Suppl 2006;4(12):146-7
   Web of Science ®Google Scholar
• Camacho LH, Hong DS, Guiterrez C, Organic arsenic in patients with advanced solid tumors: phase-1 results of ZIO-101 (s-dimethylarseno-glutatione). J Clin Oncol 2007;25(18s): abstract nr 3554
   PubMedGoogle Scholar
• Lossos I, Craig MD, Tallman MS, Novel organic arsenic molecule darinaparsin: development of IV and oral forms. J Clin Oncol 2009;27(15s):suppl abstract nr 8501
   PubMed Web of Science ®Google Scholar
• Wu J, Henderson C, Feun L, Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs 2009
   Web of Science ®Google Scholar